Description
NMS-1286937 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for various cancers; it exhibits anticancer chemotherapeutic activity. In osteosarcoma cells, NMS-1286937 induces cell cycle arrest and apoptosis and inhibits cell growth. In animal models of acute myelogenous leukemia (AML), this compound increases survival time and decreases tumor cell infiltration. Additionally, NMS-1286937 inhibits cell proliferation and induces apoptosis, cell cycle arrest, and tumor regression in cellular and animal models of colon cancer.